GE Healthcare highlights Invenia ABUS Prime and ABUS StreamVue for dense breast cancer screening.

{
  "signal_id": "5cf2c945-f35d-4379-9374-6670659d37c6",
  "signal_type": "linkedin-post-company",
  "signal_subtype": "linkedinPost",
  "detected_at": "2026-08-13T10:42:21.851+00:00",
  "company": {
    "name": "GE HealthCare",
    "domain": "gehealthcare.com"
  },
  "data": {
    "tags": [
      "Healthcare Technology",
      "Medical Research",
      "Product Launch",
      "Artificial Intelligence"
    ],
    "summary": "GE Healthcare highlights Invenia ABUS Prime and ABUS StreamVue for dense breast cancer screening.",
    "post_url": "https://www.linkedin.com/posts/gehealthcare_invenia-abus-prime-at-besoundmp4-activity-7493304793382445057-lWnW",
    "num_likes": 189,
    "post_text": "About 40% of women have dense breasts. Mammography may miss 1 in 3 cancers in this tissue type. \n\nThat's where Invenia ABUS Prime* and ABUS StreamVue* comes in - designed to support supplemental screening for women with dense breasts, with AI-driven 3D ultrasound and remote reading capabilities needed to scale across enterprise imaging networks. \n\nOne of the first U.S. installations of Invenia ABUS Prime is now live in Los Angeles at BeSound, a center focused on expanding access to supplemental breast imaging for women, including those with dense breast tissue and women under 40, an age group with rising breast cancer rates. BeSound also plans to support efforts to make breast imaging research more representative of the diverse communities it serves. \n\nTake a look at how they’re using Invenia ABUS Prime to build a breast health experience that puts women's needs first.\n\n*Invenia ABUS Prime is FDA Premarket Approved and CE Marked. ABUS StreamVue is FDA 510(k) cleared and CE Marked.",
    "initiatives": [
      {
        "topic": "supporting supplemental screening for women with dense breasts",
        "urgency": 0.7
      },
      {
        "topic": "expanding access to supplemental breast imaging",
        "urgency": 0.7
      },
      {
        "topic": "making breast imaging research representative",
        "urgency": 0.5
      }
    ],
    "pain_points": [
      {
        "topic": "mammography missing cancers in dense breasts",
        "intensity": 0.6
      },
      {
        "topic": "rising breast cancer rates in women under 40",
        "intensity": 0.4
      }
    ],
    "posted_date": "2026-08-12T13:58:01.613Z",
    "num_comments": 15,
    "technologies_mentioned": [
      {
        "name": "Invenia ABUS Prime",
        "status": "implemented"
      },
      {
        "name": "ABUS StreamVue",
        "status": "implemented"
      },
      {
        "name": "AI-driven 3D ultrasound",
        "status": "using"
      }
    ]
  }
}

curl https://signals.autobound.ai/v1/signals/5cf2c945-f35d-4379-9374-6670659d37c6 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"gehealthcare.com","limit":20}'